The development of therapies targeting biomarkers, such as epidermal growth factor receptor (EGFR)-activating mutations including deletions in exon 19 (Del19) and the single amino-acid substitution L858R in exon 21, has enabled personalized medicine for metastatic non-small cell lung cancer (NSCLC) [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.